SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership aimed at significantly reducing production costs and expanding capacity, which has driven substantial intraday stock volatility. The community is actively discussing the stock's low float and high trading volume, fueling speculation about a potential short squeeze and anticipating further upward movement as it tests key resistance levels. This partnership is seen as a crucial step for scaling their fingerprint drug screening technology ahead of anticipated future market expansion.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending due to recent discussions surrounding its integration as a fuel-discount token within the EzFill app, generating buzz about its expanding utility. The community is sharply divided, with many anticipating significant future appreciation from multi-year lows and viewing it as "digital silver," while others express frustration over its recent price action and struggle to overcome key resistance levels.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is currently a focal point for year-end tax loss selling, leading to sharp price movements and a polarized community discussion. Many foresee further declines for the meme coin, while a resilient group of long-term holders views the current dip as a strategic accumulation opportunity for future crypto cycles, with eyes on a potential rally in 2026.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending significantly following the FDA approval of NEREUS, marking the first new pharmacologic treatment for motion-induced vomiting in over four decades. The community is actively discussing the drug's potential beyond motion sickness, particularly its vast opportunity in addressing GLP-1 induced nausea, which many see as a transformative revenue driver for the company. With analysts raising price targets and whispers of potential buyout interest, investors anticipate continued upside as the market fully prices in this key regulatory win and the company's robust pipeline.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp (ESHA) is trending within a volatile low-float SPAC sector, fueled by discussions surrounding its extremely tight share float and high insider ownership. The community is actively debating its potential for rapid price movement and a short squeeze, drawing comparisons to other recently surging SPACs as new utility via a planned reward token is also highlighted.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending with significant volatility after receiving an FDA Complete Response Letter for its relacorilant drug, triggering a sharp decline in shares. The community is fiercely divided, with many calling the sell-off an overreaction given the company's existing profitable drug and deep pipeline, while others foresee further downside following analyst downgrades and a need for more clinical evidence. This binary regulatory event has intensified speculation, as investors weigh potential recovery against lingering uncertainty.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending following the FDA's acceptance and priority review of AXS-05 for Alzheimer's disease agitation, alongside positive feedback supporting an upcoming NDA for AXS-12 in narcolepsy. The market is reacting strongly to this dual pipeline advancement, with community members expressing high optimism and noting significant short-covering as a key driver of the momentum.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after a competitor's drug for Cushing's syndrome received a regulatory setback from the FDA, which the community views as a significant advantage for Xeris's approved treatment, Recorlev. This development is seen as clearing the path for Recorlev to gain market share, fueling discussions among investors about the company's long-term growth potential and undervaluation, supported by positive analyst outlooks.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is highly active following the CME Group's recent, repeated increases in margin requirements for silver futures, sparking intense debate among traders who see it as a desperate measure to control a surging market. This volatility is further fueled by conflicting narratives around impending Chinese silver export restrictions and the growing disconnect between paper and physical prices. The community is sharply divided between those predicting a massive short squeeze driven by industrial demand and global supply shifts, and those anticipating a significant pullback.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP is trending as its community intensely debates future prospects amid persistent price challenges. Significant anticipation surrounds potential regulatory clarity from the "Clarity Act" and major developments like integrations with large retailers and payment networks. Despite widespread frustration over price action, many remain bullish, highlighting AMP's core utility in secure digital payments and its existing merchant adoption as crucial for eventual upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>QOL Medical will buy Evoke for $11 per share, representing a premium of about 140% from the stock’s closing price on Monday.&nbsp;</li><li>The transaction has been approved by the boards of both companies and is expected to close by the end of 2025.</li><li>QOL Medical intends to finance the transaction with cash on hand. &nbsp;</li></ul>Shares of Evoke Pharma, Inc. (EVOK) more than doubled on Tuesday after the company said that it has entered into a definitive agreement to be acquired by privately-held QOL Medical for $11 per share.The purchase price represents a premium of about 140% from the stock’s closing price on Monday.Following the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/04/3180135/28255/en/Evoke-Pharma-Enters-into-Definitive-Agreement-to-Be-Acquired-by-QOL-Medical.html">announcement</a>, <a href="https://stocktwits.com/symbol/EVOK">EVOK shares</a> shot up 134% by Tuesday afternoon to hit $10.72 as of the time of writing, but still remained below the deal price.<h2 class="st-heading-2">Terms Of The Deal</h2>Florida-based QOL Medical will initiate a tender offer to acquire all outstanding shares of Evoke through a subsidiary. Once the tender offer is completed, a unit of QOL Medical will merge with Evoke.&nbsp;The transaction has been approved by the boards of both companies and is expected to close by the end of 2025. QOL Medical intends to finance the transaction with cash on hand.Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a chronic condition where the stomach takes too long to empty due to nerve damage caused by poorly controlled diabetes. Symptoms include nausea, vomiting, and bloating, among others.The gastric delay caused by gastroparesis can compromise absorption of orally administered medications, and until approval of Gimoti, treatment was available only in oral and injectable formulations.“GIMOTI strengthens our GI portfolio and advances our mission to support patients living with rare and underserved gastrointestinal conditions,” QOL Medical CEO Derick Cooper said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around EVOK jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:621/59;" src="data:image/png;base64,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" width="621" height="59" alt="EVOK's Sentiment Meter and Message Volume as of 1:29 p.m. ET on Nov. 4, 2025 | Source: Stocktwits"><figcaption>EVOK's Sentiment Meter and Message Volume as of 1:29 p.m. ET on Nov. 4, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user applauded the stockholders.<stembedurl>https://stocktwits.com/erb71/message/634823600</stembedurl>EVOK stock is up by 143% this year and by 87% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-recalls-over-320000-jeep-plug-in-hybrids-in-us-over-fire-risk/cL28S1PR36n">Stellantis NV Recalls Over 320,000 Jeep Plug-In Hybrids In US Over Fire Risk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

EVOK Stock Doubled In Value Today Post QOL Medical Deal, But Still Fails To Hit $11 Mark

Evoke noted that the deal reflects the strategic value of Gimoti, the company’s nasal spray for the treatment of symptoms of acute and recurrent diabetic gastroparesis in adults.

Equity

Shares of Tilray Brands (TLRY) soared 19% in the pre-market session on Thursday after the company reported adjusted net income of $3.9 million for the first quarter, marking a turnaround from a loss of $6.1 million reported in the corresponding quarter of 2024.The company’s net revenue increased 5% to $209.5 million in the quarter, driven by a rise in cannabis net revenue, and beating an analyst estimate of $206 million, according to data from Koyfin. On an adjusted basis, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/09/3164004/0/en/Tilray-Brands-Reports-Strong-First-Quarter-Fiscal-2026-Results-Highlighting-Continued-Growth-with-Record-Q1-Net-Revenue-of-210-Million-and-Net-Income.html">reported</a> nil earnings per share for the quarter, compared to a loss of $0.04 in the corresponding quarter of the last fiscal year. &nbsp;The cannabis and beverage firm also said that it reduced its total outstanding debt by $7.7 million in the three months in a bid to strengthen its balance sheet. The company ended the quarter with a cash balance of $264.8 million.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TLRY">TLRY stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.A Stocktwits user expressed hopes for the company's future, particularly in light of the possibility of positive cannabis legislation.<stembedurl>https://stocktwits.com/Family2328/message/631626082</stembedurl>Another user expects the company to hit profitability soon.<stembedurl>https://stocktwits.com/Yakish/message/631626201</stembedurl>Last month, U.S. President Donald Trump shared a video promoting cannabis use for seniors and medicaid coverage of cannabis products, sending shares of Tilray soaring.For fiscal year 2026, the company now expects to report adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $62 million to $72 million.TLRY stock is up by 29% this year and by about 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-faces-nhtsa-probe-into-2.9-million-fsd-equipped-vehicles/ch67VsCR3K9">Tesla Faces NHTSA Probe Into 2.9M FSD-Equipped Vehicles</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Tilray Brands logo is seen displayed on a smartphone and in the background.

Tilray Brands Stock Skyrockets On Swing To Profit, Significant Debt Reduction

The company said that it reduced its total outstanding debt by $7.7 million in the three months in a bid to strengthen its balance sheet.

Retail investors on Stocktwits are optimistic about Genius Group’s pivot and hope to see the same returns as MicroStrategy after the latter pivoted to a Bitcoin-first strategy in 2020. | Source: Pixabay

Why Is Genius Group Stock Rising Today?

Genius Group repurchased its stock on the open market at an average price of $0.90 per share from August 28 to September 11, 2025.

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/03/28/3051260/0/en/FDA-Issues-Complete-Response-Letter-for-Etripamil-for-PSVT.html">not approve</a> its lead investigational product, Cardamyst.The nasal spray is under development to treat episodes of abnormal heart rhythm associated with Paroxysmal supraventricular tachycardia (PSVT).The FDA highlighted two key Chemistry, Manufacturing and Controls (CMC) issues.The regulator asked the company to submit additional information on nitrosamine impurities based on the new draft guidance issued after the New Drug Application (NDA) submission. &nbsp;The agency also said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.Milestone Pharmaceuticals CEO Joe Oliveto said that the company is “deeply disappointed” by the letter but remains committed to the potential of the drug in treating patients with PSVT.“Our team is evaluating the feedback provided and intends to request a Type A meeting to discuss the issues raised in the CRL,” Oliveto said. “We are appreciative of the FDA’s efforts and are confident we can collaborate with the agency with the goal of addressing these issues in a resubmission.”The FDA did not raise any concerns regarding the drug’s clinical safety or efficacy, the company said.The nasal spray has been designed as a self-administered rapid response therapy, thereby bypassing the need for immediate medical oversight, it explained.On Stocktwits, retail investor sentiment about Milestone Pharmaceuticals dropped slightly within the ‘extremely bullish’ territory (89/100), while message volume remained at ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:652/152;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_28_at_12_10_06_PM_png_e7518f6d31.webp" alt="MIST's Sentiment Meter and Message Volume as of 12:10 p.m. ET on March 28, 2025 | Source: Stocktwits" width="652" height="152"><figcaption>MIST's Sentiment Meter and Message Volume as of 12:10 p.m. ET on March 28, 2025 | Source: Stocktwits</figcaption></figure>Following the company’s announcement, HC Wainwright kept a ‘Buy’ rating on Milestone pharmaceuticals and noted that the FDA flagged no concerns around the efficacy of the product, thereby reaffirming the integrity of the clinical data.However, the firm expects the product's launch to be delayed until the first half of 2026.<a href="https://stocktwits.com/symbol/MIST">Shares of Milestone Pharmaceuticals</a> fell over 55% this year and by over 45% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/hyperscale-data-shares-drop-despite-completing-first-nvidia-gpu-installation/chJ3iDORbEC">Hyperscale Data Stock Drops Despite Completing First Nvidia GPU Installation – But Retail Turns Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive 

The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.

Shares of education platform Genius Group&nbsp;were in the spotlight on Monday morning&nbsp;after the company&nbsp;announced that it had acquired an additional 105 Bitcoin for $10 million, bringing its total Bitcoin holdings to 319 tokens.After dropping over 2% in early morning trade, the stock was up over 4% at last check.The company reiterated its "Bitcoin-first" strategy, which was unveiled in November. Genius Group plans to allocate 90% or more of its reserves to Bitcoin, with an initial goal of accumulating $120 million worth of the cryptocurrency.&nbsp;In the six weeks since announcing the strategy, the company has spent $30 million to acquire 319.4 Bitcoin at an average price of $93,919 per token. The purchase represents 25% of the company’s initial Bitcoin target, exceeding its internal timeline.<figure class="image"><a href="https://bitcointreasuries.net/entities/genius-group" target="_blank" rel="noopener noreferrer nofollow"><img style="aspect-ratio:1251/199;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_30_104353_5fc87e866a.png" alt="Screenshot 2024-12-30 104353.png" width="1251" height="199"></a><figcaption>Genius Group's Bitcoin Purchases Over The Last 6 Weeks | Source:BitcoinTreasuries</figcaption></figure>The move mirrors the treasury strategy employed by Michael Saylor-owned MicroStrategy, which has been announcing its Bitcoin purchases every Monday.&nbsp;Genius Group's CEO has framed the shift as a long-term commitment to the digital asset, emphasizing its role in safeguarding company reserves amid a volatile economic climate.<figure class="image"><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_30_105112_8808c47a6c.png" alt="Screenshot 2024-12-30 105112.png"><figcaption>Genius Group Ltd. Sentiment and Message Volume on Dec 30 as of 10:50 a.m. ET | Source: Stocktwits</figcaption></figure>On Stocktwits, retail sentiment around Genius Group improved to ‘bullish’ from ‘neutral’ as chatter also increased to ‘normal’ levels from ‘level’ a day ago.&nbsp;Users debated whether or not the current levels of dilutions are sustainable.<stembedurl>https://stocktwits.com/sunkissed1/message/598192228</stembedurl><stembedurl>https://stocktwits.com/Mysticx24/message/598185932</stembedurl>Others celebrated that the company now has Bitcoin worth $30 million in its coffers.&nbsp;<stembedurl>https://stocktwits.com/EarlofLondon/message/598180299</stembedurl><stembedurl>https://stocktwits.com/warrants_Moon/message/598175305</stembedurl><stembedurl>https://stocktwits.com/22Shares/message/598179161</stembedurl>According to the company, the next step is to focus on maximizing its BTC Yield – a Bitcoin Treasury key performance indicator (KPI), initiated by Saylor for Microstrategy.“Now, with a focus on BTC Yield KPI, we are considering various investment and finance options that maximize shareholder value whilst accelerating our progress in building our Bitcoin Treasury,” said CEO Roger Hamilton.Since November, the company has achieved a BTC Yield of 1,646% so far.&nbsp;However, the stock has dipped nearly 90% this year, trading near its 52-week low of $0.51 and far from its 52-week high of $7.08.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mara-riot-hut-crypto-stocks-take-a-hit-as-bitcoin-dips/cJOiPdWRkf">Bitcoin’s Drop To $93K Drags BTC Mining Stocks: Retail Sentiment Remains Frosty</a>

Genius Group Stock Swings After Announcing Bitcoin Buy Worth $10M: Retail Sentiment Improves

In the six weeks since announcing its shift in its treasury strategy, Genius Group has spent $30 million to acquire 319.4 Bitcoin.

Several cannabis stocks dived on Wednesday after Democrat Vice President Kamala Harris lost to Republican candidate Donald Trump, who will return for a second term in the White House to become the 47th U.S. president.Harris was seen as having a favorable take on the recreational use of Cannabis, which many Republican states have yet to legalize.On Wednesday, the state of Florida voted against one such move that would have legalized marijuana for recreational use to adults 21 years of age and older from medical marijuana treatment centers and other state-licensed entities, Reuters <a target="_blank" rel="noopener noreferrer nofollow" href="https://reported.">reported.</a>Florida was seen as a &nbsp;“very attractive market,” Reuters reported citing an estimate from cannabis analytics company Headset <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/markets/us/pot-stocks-dive-florida-rejects-legalization-recreational-marijuana-2024-11-06/">indicating</a> $4.9 billion to $6.1 billion in adult-use sales during the first year of implementation.Cannabis-focused stocks such as Tilray Brands ($TLRY) and Trulieve ($TCNNF) were down 14% and 39% respectively as of 1:55 pm ET. &nbsp;Trulieve had also provided funding worth $145 million as of October towards the Florida campaign, Associated Press <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/florida-ballot-measures-for-abortion-rights-legalized-marijuana-fail-f70b1bbe?mod=home-page&amp;mod=article_inline">reported.</a>Other stocks that saw declines include US-listed SNDL Inc. ($SNDL) and Cronos Group ($CRON) were down 14% and 9%, respectively as of 2:20 pm ET. &nbsp;While shares of Canada-based Aurora Cannabis Inc. ($ACB) were down more than 17% as of 2:45 pm ET.To be sure, Trump’s choice of who replaces the current attorney general and the possibility of a more moderate senate majority leader may still bring favor to the industry.Twenty four American states have legalized cannabis for recreational use, with 39 states where Cannabis use is allowed for medical purposes.Many Stocktwits users were hopeful of a bounce back.<stembedurl>https://stocktwits.com/RizzaSizzler/message/591429531</stembedurl><stembedurl>https://stocktwits.com/Goldenleaf/message/591435127</stembedurl><stembedurl>https://stocktwits.com/CoBear/message/591441354</stembedurl> &nbsp;For updates and corrections, email newsroom@stocktwits.com.&nbsp;

Cannabis-focused companies like $CRON, $ACB, $SNDL saw stocks slip | Source: Pexels

 US Election 2024: Cannabis Stocks Feel Trump Effect, But Retail's Hopes Stay High

Harris was seen as having a favorable take on the recreational use of Cannabis

Shares of Canada-based Aurora Cannabis Inc. ($ACB) jumped more than 2% on Tuesday, ahead of the cannabis producer’s third-quarter earnings, lifting retail sentiment.Edmonton, Canada-based Aurora makes cannabis and cannabis-derived products sold under brands such as ‘Cannimed’, “Bidiol’ and ‘Being.’Wall Street analysts expect Aurora to report earnings per share (EPS) of $0.08 on estimated revenues of $50.73 million.Retail sentiment on the stock has inched lower compared to a day ago but remains ‘extremely bullish,’ with ‘high’ message volumes.<figure class="image"><img style="aspect-ratio:1316/352;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_11_06_at_5_38_03_AM_1920c18130.png" alt="Screenshot 2024-11-06 at 5.38.03 AM.png" width="1316" height="352"><figcaption>ACB sentiment meter and message volumes on Nov 5 as of 7:09 pm ET</figcaption></figure>According to The Fly.com, Aurora was seeing ‘bullish’ option flow with 4,183 calls trading, 2.0x expected, and implied volume increasing over 32 points to 379.40%.Earlier this week, BofA said broad-based tariffs were likely under a Trump win that will influence consumer stocks including cannabis stocks. According to the firm, a broad cannabis reform is likely with relaxed regulatory standards. Several cannabis-focused companies stand to benefit from this including Aurora, CV Sciences ($CVSI), and Truelieve Cannabis (TCNNF).Many Stocktwits users were upbeat about the company’s stock even with the regulatory uncertainty related to the election outcomes.<stembedurl>https://stocktwits.com/NoFearHere/message/590887046</stembedurl><stembedurl>https://stocktwits.com/Peteey/message/590812825</stembedurl>Aurora stock is up 28.74% year-to-date.For updates and corrections, email newsroom@stocktwits.com&nbsp;

Wall Street analysts expect Aurora to report earnings per share (EPS) of $0.08 on estimated revenues of $50.73 million.| Image source: Pixabay

Aurora Cannabis Stock Surges Ahead of Q3 Earnings: Retail Sentiment Strong

Retail sentiment on the stock has been strong, with ‘extremely bullish’ sentiment scores and ‘high’ message volumes.

GWX
SPDR S&P International Small Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GWX News

GWXSPDR S&P International Small Cap ETF